GlassScriptPhysician profile
Lori M Dulabon
NPI 1043477334
$3,962.51
in general payments reported to CMS, 2019-2025
36 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $272 · 2021: $553 · 2022: $728 · 2023: $717 · 2024: $566 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $830.83 | 2019-2024 | Myrbetriq, Veozah |
| Axonics, INC. | $735.72 | 2021-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $671.26 | 2023-2025 | Gemtesa, Orgovyx |
| Urovant Sciences INC | $201.75 | 2021-2022 | |
| Medtronic, INC. | $197.18 | 2025 | Interstim, Endurant Iis |
| Myovant Sciences INC. | $166.33 | 2021-2022 | |
| Smith+Nephew, INC. | $113.26 | 2023-2025 | Stravix, Grafix Pl, Stravix Pl |
| Olympus America INC. | $111.53 | 2023-2025 | Itind System, Uretero-Reno Fiberscope, Olympus |
| Boston Scientific Corporation | $96.45 | 2023-2025 | Axonics, Lithovue |
| Amag Pharmaceuticals, INC. | $96.42 | 2019 | |
| Pfizer INC. | $92.03 | 2020-2022 | |
| Janssen Biotech, INC. | $91.96 | 2019-2023 | |
| Becton, Dickinson and Company | $56.73 | 2023-2025 | Aptra, Bard Urinary Drainage Bag |
| C. R. Bard, INC. & Subsidiaries | $43.69 | 2022-2023 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Abbott Laboratories | $41.11 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.24 | 2020-2021 | |
| Shockwave Medical, INC | $29.66 | 2025 | |
| 180 Medical, INC. | $26.11 | 2025 | |
| Lilly USA, LLC | $21.46 | 2022 | |
| Tolmar, INC. | $21.10 | 2023 | |
| Convatec INC. | $20.97 | 2023 | |
| Urogen Pharma, INC. | $20.49 | 2023 | Jelmyto |
| Vertex Pharmaceuticals Incorporated | $20.26 | 2024 | |
| Endo Pharmaceuticals INC. | $18.90 | 2019 | |
| Medtronic USA, INC. | $16.65 | 2019 | |
| Neotract INC. | $16.63 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.24 | 2020 | |
| Valencia Technologies Corporation | $15.54 | 2025 | Ecoin Device Kit |
| Laborie Medical Technologies Corp. | $15.27 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Tolmar Pharmaceuticals, INC. | $15.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2022 | |
| Heraeus Medical, LLC. | $14.08 | 2019 | |
| Clovis Oncology, INC. | $12.96 | 2020 | |
| Bioventus LLC | $12.02 | 2020 | |
| Coloplast Corp | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Dulabon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.